Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 376, P. 286 - 302
Published: Oct. 16, 2024
Language: Английский
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7028 - 7028
Published: June 27, 2024
Nanomedicine could improve the treatment of diabetes by exploiting various therapeutic mechanisms through use suitable nanoformulations. For example, glucose-sensitive nanoparticles can release insulin in response to high glucose levels, mimicking physiological insulin. Oral nanoformulations for uptake via gut represent a long-sought alternative subcutaneous injections, which cause pain, discomfort, and possible local infection. Nanoparticles containing oligonucleotides be used gene therapy cell stimulate production β-cells or β-like cells modulate responses T1DM-associated immune cells. In contrast, viral vectors do not induce immunogenicity. Finally, diabetic wound healing, delivery regenerative molecules tissue repair thus provide valuable tool treat this complication. Here, we describe these different approaches with their potential clinical application.
Language: Английский
Citations
7
Clinical Reviews in Allergy & Immunology, Journal Year: 2025, Volume and Issue: 68(1)
Published: Feb. 11, 2025
Language: Английский
Citations
0
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: March 17, 2025
Treating autoimmune diseases without nonspecific immunosuppression remains challenging. To prevent or treat these conditions through targeted immunotherapy, we developed a clinical-stage nanoparticle platform that leverages the tolerogenic capacity of liver sinusoidal endothelial cells (LSECs) to restore antigen-specific immune tolerance. In vivo efficacy was evaluated in various CD4+ T cell-mediated disease models, including preventive and therapeutic models myelin oligodendrocyte glycoprotein-induced experimental encephalomyelitis (EAE), ovalbumin-sensitized delayed-type hypersensitivity (DTH), spontaneous type 1 diabetes model. Nanoparticle-induced responses were also analyzed adoptive transfers 2D2 transgenic into wild-type mice, followed by administration. The peptide-conjugated nanoparticles displayed uniform size distribution (25-30 nm). Their coupling efficiency for peptides with unfavorable physicochemical properties significantly enhanced proprietary linker technology. Preferential LSEC targeting coupled fluorescently labeled confirmed via intravital microscopy flow cytometry. Intravenous administration reduced severity demyelination EAE, independent prednisone at maintenance doses, suppressed target tissue inflammation DTH Furthermore, prophylactic mixture five autoantigenic lowered hyperglycemia incidence non-obese diabetic mice. Mechanistically, tolerizing effects associated induction regulatory cell anergy, which counteract proinflammatory tissue. Our findings demonstrate peptide-loaded preferentially deliver disease-relevant LSECs, thereby inducing This versatile holds promise clinical application across multiple diseases.
Language: Английский
Citations
0
Frontiers in Cardiovascular Medicine, Journal Year: 2025, Volume and Issue: 12
Published: March 20, 2025
RNA therapeutics are emerging as a promising approach for cardiovascular diseases (CVDs) management, offering targeted gene regulation through modalities like mRNA, siRNA, and miRNA. In recent years, researchers have conducted lot of research on the application technology in treatment CVDs. Despite hurdles off-target effects immune responses, clinical trial outcomes encouraging. This review synthesizes current progress CVDs, examining their mechanisms, advantages, challenges delivery safety. We highlight potential personalized medicine, combination artificial intelligence (AI) bioinformatics advancing therapeutics. The future CVDs is poised significant impact, necessitating continued interdisciplinary collaboration to optimize these treatments ensure patient safety efficacy.
Language: Английский
Citations
0
Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown, P. 113641 - 113641
Published: March 1, 2025
Language: Английский
Citations
0
Future Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 17
Published: April 15, 2025
The challenges in drug discovery aiming to mitigate cancer progression are the thrust area of scientific research for several decades. Since advent heterocyclic chemistry, programs have made significant achievements that lead development numerous drugs with broad spectrum potencies, contributing both diagnostic and therapeutic advancements. Till date, efforts discover more potent efficient candidates underway minimize adverse side effects existing chemotherapeutics. In view above, small-molecule agonists can interact different immune modulators like toll receptor-7 (TLR-7) TLR-8 being investigated explored. These expected display profound effect on anti-tumoral activity by enhancing production proinflammatory cytokines. Recently, imidazoquinoline derivatives proven TLR agonist activities emerged as promising anticancer therapeutics. With advancements technology evolution new scopes discovery, strategies adopted, particularly help nanotechnology, immune-technology, combination etc., curb various types cancers. Herein, novel therapeutics imidazoquinolines reported last 5 years, their structure-activity relationship along important synthetic schemes agonists, discussed.
Language: Английский
Citations
0
European Journal of Immunology, Journal Year: 2024, Volume and Issue: 54(12)
Published: Sept. 16, 2024
Lipid nanoparticles (LNPs) have emerged as the preeminent nonviral drug delivery vehicles for nucleic acid therapeutics, exemplified by their usage in mRNA COVID-19 vaccines. As a safe and highly modular platform, LNPs are attractive wide range of applications. In addition to vaccines, being utilized platforms other immunoengineering efforts, especially cancer immunotherapies modulating immune cells functionality via delivery. this review, we focus on methods applications LNP-based immunotherapy five cell types: T cells, NK macrophages, stem dendritic cells. Each these types has wide-reaching but comes with unique challenges barriers. By combining knowledge immunology nanotechnology, can be developed improved targeting transfection, ultimately working toward novel clinical therapeutics.
Language: Английский
Citations
2
Drug Delivery and Translational Research, Journal Year: 2024, Volume and Issue: 14(10), P. 2930 - 2944
Published: June 11, 2024
Language: Английский
Citations
1
Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 376, P. 286 - 302
Published: Oct. 16, 2024
Language: Английский
Citations
1